Breaking News Headlines Today | Ground News

See every side of every news story

bariatricnews.net image

News from bariatricnews.net

The Ground News media bias check for bariatricnews.net is unknown. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides.

Is bariatricnews.net credible or reliable? Our Factuality score answers both of those questions. When it comes to bariatricnews.net, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about bariatricnews.net

Where is bariatricnews.net located?bariatricnews.net's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top bariatricnews.net News

Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints

Obesity · Suzhou

Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints

76% Center coverage: 17 sources

SAN FRANCISCO and SUZHOU, China, Nov. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces…See the Story

High Blood Pressure Rates Double Among Children & Teens

High Blood Pressure Rates Double Among Children & Teens

44% Left coverage: 16 sources

Key Takeaways See the Story

Viking Therapeutics Concludes Enrolment in Phase III Trial of Obesity Therapy

Viking Therapeutics Concludes Enrolment in Phase III Trial of Obesity Therapy

Viking Therapeutics has concluded participant enrolment in its Phase III VANQUISH-1 trial of subcutaneous VK2735, which is being developed to potentially treat metabolic disorders such as obesity.The post Viking Therapeutics concludes enrolment in Phase III trial of obesity therapy appeared first on Clinical Trials Arena.See the Story

Breaking News Topics Related to bariatricnews.net